Hemab Therapeutics (NASDAQ:COAG) Upgraded by HC Wainwright to Strong-Buy Rating

HC Wainwright upgraded shares of Hemab Therapeutics (NASDAQ:COAG) to a strong-buy rating in a report published on Wednesday morning,Zacks.com reports.

A number of other research firms also recently issued reports on COAG. Jefferies Financial Group initiated coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $39.00 price target on the stock. Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th. Zacks Research upgraded shares of Hemab Therapeutics to a “hold” rating in a report on Wednesday, May 27th. Evercore started coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 target price on the stock. Finally, The Goldman Sachs Group started coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $36.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $41.40.

Hemab Therapeutics Stock Up 3.7%

Shares of NASDAQ:COAG opened at $26.45 on Wednesday. Hemab Therapeutics has a fifty-two week low of $23.00 and a fifty-two week high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last issued its earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share for the quarter.

Insider Activity at Hemab Therapeutics

In related news, Director Ra Capital Management, L.P. acquired 2,675,000 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The stock was purchased at an average cost of $18.00 per share, with a total value of $48,150,000.00. Following the transaction, the director directly owned 6,149,096 shares of the company’s stock, valued at $110,683,728. This trade represents a 77.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders have purchased 2,970,541 shares of company stock valued at $55,459,603.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.